Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analysts

Worry not, Wegovy fans: There’s reason to believe supply of Novo Nordisk’s obesity med could resume as planned by the middle of the year. That’s according to Jefferies analysts’ chat with a manufacturing expert, who weighed in on the FDA write-up at a Catalent facility behind the production dilemma.